Mr. Rene Goehrum reports

BIOSYENT PHARMA SIGNS EXCLUSIVE LICENSING AND DISTRIBUTION AGREEMENT FOR NEW URGENT CARE DRUG PRODUCT

BioSyent Inc.'s subsidiary, BioSyent Pharma Inc., has signed an exclusive licensing and distribution agreement with an existing European partner for a new product that will be marketed by its hospital products division. The new product utilizes a patented delivery system that offers technical advantages over existing alternatives and will be used in hospitals and acute care settings. These products will provide hospitals, clinics and health care professionals with improved patient safety, as well as operational efficiencies. The product will be launched after Health Canada approval.

"This is the third product that we have in-licensed from the same partner that uses the same underlying patented technology. The first of the three is already approved and being prepared for launch later this year or early next, and the second is in the latter stages of the Health Canada approval process," said Rene Goehrum, president and chief executive officer of BioSyent. "We have already started discussions and due diligence with our European partner on the fourth product that utilizes this technology, and we are aware that they are developing more such products. This new product deal brings the combined number of products that BioSyent Pharma has either in market, Health Canada approved, or in-licensed, to eight."

We seek Safe Harbor.